Your Cholesterol Won't Budge. Your Genes May Be Why.

APOE encodes apolipoprotein E, a protein your liver uses to package and clear cholesterol from your bloodstream. Think of it as a postal worker: it attaches to cholesterol particles and directs them to receptors that pull them into cells for disposal or recycling. Your APOE comes in three flavors: e2, e3, and e4. Most people carry e3, which works normally.

The e4 variant, carried by roughly 25% of people with European ancestry, makes your liver less efficient at clearing LDL and cholesterol-rich remnant particles. The e4 allele dramatically increases the stickiness and oxidation of LDL particles, making them more likely to lodge in artery walls. If you carry even one e4, your baseline LDL clearance is impaired. If you carry two (e4/e4), the problem is severe.

You notice this as stubbornly elevated cholesterol despite a clean diet, or as LDL that drops modestly on statins while your friends’ LDL plummets. You may also notice your total cholesterol tends to climb with age, or that you react more strongly to dietary cholesterol than others do. Your arteries are more vulnerable to buildup because your liver simply cannot process the cholesterol efficiently.

PCSK9 is a protein that hunts down LDL receptors on your cell surface and destroys them. When receptors are destroyed, your cells cannot pull LDL from the bloodstream, and LDL accumulates. Normally, PCSK9 works moderately, keeping receptor turnover balanced. Gain-of-function variants in PCSK9 make the protein hyperactive, destroying receptors faster than your body can replace them.

These gain-of-function variants occur in roughly 1-3% of the population and cause markedly elevated LDL levels that resist dietary intervention entirely. If you have a PCSK9 gain-of-function variant, statins help but may not be enough, because the drug only inhibits cholesterol production; it does not stop PCSK9 from destroying receptors. Your LDL stays high because your cells are essentially blind to the cholesterol circulating outside them.

You experience this as LDL in the 180-250 range that barely budges with medication, or as a family history of early heart attacks despite everyone taking statins. Dietary changes feel pointless. You may have been told your cholesterol is “genetic” and that you simply need higher drug doses, but you’ve never been told why the standard doses fail.

LDLR encodes the LDL receptor itself, the protein that sits on cell surfaces and grabs LDL cholesterol from the bloodstream to bring it inside. Without enough functional receptors, your cells cannot clear LDL, and it accumulates to dangerous levels. Pathogenic variants in LDLR occur in over 1,000 different forms and cause familial hypercholesterolemia (FH), a condition affecting roughly 1 in 300 people.

Familial hypercholesterolemia comes in two forms. Heterozygous FH (one mutated copy) causes LDL levels typically 2-3 times higher than normal despite diet and medication. Homozygous FH (two mutated copies) is rare but severe, with LDL levels 6-10 times normal, often accompanied by physical signs like tendon xanthomas and corneal arcus. The problem is straightforward: your cells literally cannot grab cholesterol from the blood efficiently.

You likely know you have FH already, as it usually runs visibly through families. But many people carry a heterozygous mutation without knowing it, chalking up lifelong high cholesterol to “bad genes” while only taking moderate-dose statins. If FH was never formally diagnosed, you may have suffered decades of unnecessary cardiovascular risk.

APOB encodes apolipoprotein B, the structural protein that allows LDL particles to bind to LDL receptors. Imagine APOB as the handle on a package: without the handle, the receptor cannot grab the package, even if the package is right there. Most APOB works normally, but certain variants, like R3527Q, create a defective protein that the receptor cannot recognize.

APOB mutations account for roughly 5% of familial hypercholesterolemia cases. People with defective APOB produce LDL particles that circulate in the bloodstream unchanged, even though their livers are working normally and their LDL receptors are functional. The disconnect between machinery and outcome is cruel: your cells are reaching for cholesterol particles that your receptors literally cannot see. Standard cholesterol metabolism breaks down completely.

You experience this as lifelong high LDL despite excellent diet and a family history of elevated cholesterol. You may have been tested for FH and found normal LDLR, leaving you and your doctor confused about why your cholesterol is so high. Blood tests look normal; your liver works fine; your receptors work fine. The problem is the particles themselves.

CETP encodes cholesteryl ester transfer protein, an enzyme that moves cholesterol back and forth between different types of cholesterol particles (HDL, LDL, triglycerides). Think of it as a shuttle service: it delivers cholesterol from protective HDL particles to less-protective particles, and vice versa. The process normally maintains balance, but variants like TaqIB and I405V slow CETP down.

Roughly 40% of people carry CETP variants that reduce enzyme activity. This sounds beneficial at first: lower CETP activity means more cholesterol stays in protective HDL, so your HDL rises. However, it also means LDL particle composition shifts unfavorably, and you end up with more small, dense LDL particles that are more likely to lodge in artery walls. The higher HDL masks a worse lipid picture overall.

You may notice this pattern: your HDL is surprisingly high for someone who does not exercise much, but your LDL remains problematic, or your doctor expresses concern despite your “good” HDL numbers. Triglycerides may also be elevated. You feel like your lipid panel is contradictory, as if the numbers do not tell a coherent story.

LPA encodes lipoprotein(a), a particle that resembles LDL but is far more atherogenic, meaning it damages arteries more aggressively. Lp(a) is almost entirely genetically determined; lifestyle and diet barely move it. Roughly 20% of people have elevated Lp(a), meaning levels above 50 mg/dL. If you are in that group, you carry a lifelong, independent cardiovascular risk factor that standard cholesterol management barely addresses.

Elevated Lp(a) is a powerful predictor of early heart attacks and strokes, sometimes more predictive than LDL itself. The particle promotes blood clot formation, inflammation, and plaque oxidation inside arteries. Standard statins do not lower Lp(a); in fact, they sometimes raise it slightly. You could have normal LDL and high Lp(a) and still face high cardiovascular risk, yet most doctors never check Lp(a) and have no protocol for managing it.

You may have a family history of early heart disease despite good cholesterol numbers, or you may have suffered a heart attack or stroke while your lipid panel looked reasonable. You likely felt unheard when you mentioned family history, because the narrative around cholesterol centers on LDL, not this more sinister particle.